SEC Form SC 13G filed by Atara Biotherapeutics Inc.

$ATRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ATRA alert in real time by email
SC 13G 1 tm249099d1_sc13g.htm SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G*

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. __)*

 

Atara Biotherapeutics, Inc.

(Name of Issuer)
 

Common Stock, par value $0.0001 per share (the “Shares”)

(Title of Class of Securities)
 

046513107

(CUSIP Number)
 

March 8, 2024

(Date of Event Which Requires Filing of the Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 046513107 13G Page 2 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     ¨

(b)     ¨

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,512,063 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.4%1

12.

TYPE OF REPORTING PERSON

 

IA; OO; HC

 

 

1 The percentages reported in this Schedule 13G are based upon 101,922,250 Shares outstanding as of October 27, 2023 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 1, 2023). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on March 18, 2024.

 

 

 

 

                 CUSIP No. 046513107 13G Page 3 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors Holdings LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,512,063 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.4%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

CUSIP No. 046513107 13G Page 4 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,512,063 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.4%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

CUSIP No. 046513107 13G Page 5 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

21,056 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

BD; OO

       

 

 

 

CUSIP No. 046513107 13G Page 6 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities Group LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

21,056 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

CUSIP No. 046513107 13G Page 7 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

21,056 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

CUSIP No. 046513107 13G Page 8 of 13 Pages

 

1.

NAME OF REPORTING PERSONS

 

Kenneth Griffin

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

3. SEC USE ONLY
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

U.S. Citizen

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,533,119 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.4%

12.

TYPE OF REPORTING PERSON

 

IN; HC

       

 

 

 

CUSIP No. 046513107 13G Page 9 of 13 Pages

 

Item 1(a). Name of Issuer:
   
 

Atara Biotherapeutics, Inc.

   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320

   
Item 2(a). Name of Person Filing:
   
  This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
   
  Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
   
  The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
   
Item 2(b). Address or Principal Business Office or, if none, Residence:
   
  The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
   
Item 2(c). Citizenship:
   
  Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
   
Item 2(d). Title of Class of Securities:
   
 

Common Stock, par value $0.0001 per share

   
Item 2(e). CUSIP Number:
   
 

046513107

 

 

 

CUSIP No. 046513107 13G Page 10 of 13 Pages

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
   
  (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
  (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
         
  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
         
Item 4. Ownership:
         
  A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
         
    (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 6,512,063 Shares.
         
    (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 6.4% of the Shares outstanding.
         
    (c) Number of Shares as to which such person has:
         
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  6,512,063
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  6,512,063

 

 

 

 

CUSIP No. 046513107 13G Page 11 of 13 Pages

 

  B. Citadel Securities LLC
         
    (a) Citadel Securities LLC may be deemed to beneficially own 21,056 Shares.
       
    (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  21,056
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  21,056
         
  C. Citadel Securities Group LP and Citadel Securities GP LLC
         
    (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 21,056 Shares.
       
    (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  21,056
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  21,056
         

 

 

 

CUSIP No. 046513107 13G Page 12 of 13 Pages

 

  D. Kenneth Griffin
         
    (a) Mr. Griffin may be deemed to beneficially own 6,533,119 Shares.
       
    (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 6.4% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  6,533,119
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  6,533,119

 

Item 5. Ownership of Five Percent or Less of a Class:
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
   
  Not Applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group:
   
  Not Applicable
   
Item 9. Notice of Dissolution of Group:
   
  Not Applicable
   
Item 10. Certifications:
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

CUSIP No. 046513107 13G Page 13 of 13 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated March 18, 2024.

 

CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
         
By: /s/ Guy Miller   By: /s/ Seth Levy
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
         
         
CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP
         
By: /s/ Guy Miller   By: /s/ Seth Levy
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
         
         
CITADEL SECURITIES GP LLC   CITADEL GP LLC
         
By: /s/ Guy Miller   By: /s/ Seth Levy
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
         
         
      KENNETH GRIFFIN
         
      By: /s/ Seth Levy
        Seth Levy, attorney-in-fact*

 

 

*Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

 

 

Get the next $ATRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATRA

DatePrice TargetRatingAnalyst
11/9/2023Outperform → In-line
Evercore ISI
11/9/2023Buy → Neutral
H.C. Wainwright
11/9/2023$31.00 → $1.00Buy → Neutral
Mizuho
7/20/2022$8.00 → $3.00Neutral → Sell
Citigroup
7/13/2022$10.00Overweight → Neutral
JP Morgan
7/13/2022$16.00 → $5.00Buy → Hold
Stifel
5/10/2022$15.00 → $8.00Buy → Neutral
Citigroup
1/3/2022$26.00 → $27.00Overweight
JP Morgan
More analyst ratings

$ATRA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

    Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources Strategic review by financial advisor ongoing Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, bus

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 1,350 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of February 3, 2025, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock u

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

    U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Atara's active Investigational New Drug (IND) applications. These INDs include the EBVALLOTM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ATRA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ATRA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATRA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATRA
SEC Filings

See more

$ATRA
Leadership Updates

Live Leadership Updates

See more
  • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations
  • Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial laun

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ATRA
Financials

Live finance-specific insights

See more
  • Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

    Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At

    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ATRA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more